Vijay Chilakamarri, MD
Interventional Cardiology · Fort Wayne, INNPI 1548230758
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Endologix LLC at 30.0% of the total. Reporting peaked in 2019 at $8,704 and has fallen 89.4% since, to $926 in 2025.
Across 208 payments — averaging $101.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Endologix LLC$6K
- Bard Peripheral Vascular, Inc.$4K
- Medtronic$4K
- Boston Scientific$1K
- Shockwave Medical, Inc$1K
- Philips North America LLC$781
- plus $4K from 27 others
Across 46 payments — averaging $723.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$26K
- Boston Scientific$7K
What the payments were for
- Consulting fees$9,60045%
- Travel & lodging$4,50721%
- Food & beverage$7,07533%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Endologix LLC | 12 | $6,358 |
| Bard Peripheral Vascular, Inc. | 1 | $4,200 |
| Medtronic(2 entities) | 33 | $3,745 |
| Boston Scientific | 15 | $1,296 |
| Shockwave Medical, Inc | 24 | $1,099 |
| Philips North America LLC | 8 | $781 |
| Edwards Lifesciences | 9 | $767 |
| Abbott | 10 | $532 |
| Penumbra, Inc. | 5 | $440 |
| Novartis | 11 | $190 |
| Amgen | 14 | $183 |
| Angiodynamics, Inc. | 4 | $178 |
| Cardiovascular Systems Inc. | 2 | $173 |
| Johnson & Johnson | 11 | $143 |
| Pfizer | 9 | $139 |
| ZOLL Respicardia, Inc. | 1 | $136 |
| Biotronik Inc. | 2 | $117 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $102 |
| Merck | 5 | $95 |
| Heartflow, Inc. | 2 | $93 |
| AstraZeneca | 5 | $73 |
| Chiesi USA, Inc. | 4 | $59 |
| Cook Medical LLC | 1 | $50 |
| Boehringer Ingelheim | 3 | $46 |
| Scpharmaceuticals Inc. | 2 | $33 |
| Terumo Medical Corporation | 1 | $28 |
| Canon Medical Systems USA, Inc. | 1 | $27 |
| Stryker | 1 | $22 |
| Abiomed | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Vifor Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ovation$5,852
- LUTONIX$4,200
- CoreValve Evolut$1,310
- Valiant Captivia$1,197
- GENERAL - THERAPIES$898
- Azurion 7 M20$696
- PASCAL$237
- Indigo System$228
- Diamondback Peripheral$165
- Diamondback Coronary$165
- SAPIEN 3 Ultra RESILIA$142
- COROFLOW$141
- Alto Abdominal Stent Graft System$137
- remede System$136
- NAVITOR$132
- Amplatzer Cardiac Plug$126
- POD$125
- CG Future$117
- Auryon Laser System 100-120 Vac$114
- Orsiro Mission$104
How this compares
$21,182 in reported general payments places this provider in the 80th percentile of 170 interventional cardiology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 116 | $142,094 |
| Repatha SureclickEvolocumab | 45 | $50,380 |
| XareltoRivaroxaban | 29 | $42,720 |
| BrilintaTicagrelor | 31 | $24,537 |
| EntrestoSacubitril/Valsartan | 16 | $23,625 |
| Ezetimibe | 205 | $3,620 |
| Metoprolol Succinate | 196 | $2,768 |
| Atorvastatin Calcium | 290 | $2,319 |
| ClopidogrelClopidogrel Bisulfate | 172 | $1,456 |
| Ranolazine ErRanolazine | 15 | $1,425 |
| Rosuvastatin Calcium | 122 | $1,128 |
| Losartan Potassium | 74 | $1,032 |
| Potassium Chloride | 13 | $973 |
| Carvedilol | 112 | $943 |
| Amlodipine Besylate | 124 | $726 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $139 | $142,094116 claims |
| Johnson & JohnsonXarelto | $143 | $42,72029 claims |
| AstraZenecaBrilinta | $73 | $24,53731 claims |
| NovartisEntresto | $190 | $23,62516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 170 interventional cardiology providers in Indiana.
Other interventional cardiology in Fort Wayne
- Muzammil MusaniFort Wayne$184K
- Christopher SmitsonFort Wayne$24K
- Samer AbbasEast Chicago$395K
- James HermillerIndianapolis$307K
- Woodrow CoreyIndianapolis$262K
- Dean FerreraEast Chicago$180K
- Shashidhar DivakaruniMunster$97K
- Jarrod FrizzellEvansville$86K
- Navneet LatherNoblesville$83K
- Michael BallIndianapolis$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.